High blood pressure: why it happens, what a pill buys you, and why “just change your lifestyle” isn’t a plan for everyone

Updated 28 October 2026: new sections on what causes high blood pressure, the “root cause” pitch, what the 2025 guideline tells doctors to do, how many years treatment buys, and who dies of it first.

The number that kills quietly

Almost half of American adults, 47.7%, have high blood pressure under the current definition (130/80 or higher). Most feel nothing. Among adults under 40 who have it, only about 1 in 4 know. In 2024 it was a primary or contributing cause of 680,179 deaths in the US.

A lot of people with high blood pressure hear some version of the same advice, from doctors and, increasingly, from the internet: cut the salt, lose weight, try something natural, and you won't need a pill. Some go further and say the pills are the problem. The most popular version sounds the smartest: doctors just mask the symptom with a pill; we find and treat the root cause.

To judge that advice, you need to know what high blood pressure actually is.

What blood pressure is

Blood pressure is the force of blood pushing on the walls of your arteries. The top number (systolic) is the pressure when your heart squeezes; the bottom number (diastolic) is the pressure while it refills.

How high it runs depends on three things: how much blood the heart pumps, how tight or stiff the arteries are, and how much salt and water the body is holding on to. Your brain, your hormones and your kidneys adjust all three every second.

Minute to minute, the nervous system does the steering. Over days and years, the kidneys have the final say. The physiologist Arthur Guyton showed that the kidney-fluid system is "the dominant method of establishing long-term pressure control." When pressure rises, healthy kidneys respond by letting more salt and water go (doctors call this pressure natriuresis); the blood volume falls and the pressure comes back down. When pressure falls, they hold on to more. It is a thermostat.

High blood pressure is what happens when that thermostat is reset higher. The kidneys now need a higher pressure before they will release the same amount of salt and water, so the body settles at the higher number and defends it. Research suggests that every form of high blood pressure, including the kind that comes with excess weight, involves this resetting. That is why it doesn't go away on its own, and why a one-off "cleanse" or a week of eating well doesn't reset it.

Several systems can push the thermostat up:

• The renin–angiotensin–aldosterone system (RAAS). The kidneys release renin, which starts a chain that ends in angiotensin II, a hormone that squeezes arteries, and aldosterone, a hormone that opens sodium channels in the kidney so more salt is kept. Too much of either raises pressure.
• The sympathetic ("fight or flight") nervous system. It is generally more active in people with high blood pressure. Over time it doesn't just tighten arteries; it also makes their muscular walls thicken and stiffen.
• The lining of the arteries. Healthy artery lining releases nitric oxide, which relaxes the vessel. When that lining stops working properly, it makes less nitric oxide and the vessels relax less. People who are "salt-sensitive" tend to have this kind of damage.

These systems feed each other. High pressure injures the artery lining and the kidneys, and injured arteries and kidneys push the pressure higher. That vicious circle is the reason untreated blood pressure tends to climb with time.

US guidelines sort readings into four groups:

• Normal: under 120/80
• Elevated: 120–129 on top, under 80 on the bottom
• Stage 1 high blood pressure: 130–139 or 80–89
• Stage 2 high blood pressure: 140 or more, or 90 or more

Why it goes up: a mosaic, not one cause

For about 90–95% of people with high blood pressure, there is no single cause. Doctors call this "primary" or "essential" hypertension. In 1949, the physician Irvine Page described it as a mosaic: many mechanisms, each contributing a piece. Seventy-five years of research have only added pieces.

• The kidneys. They hold on to more salt and water than they should, so there is more fluid in the pipes. Excess weight makes this worse, partly by pressing on the kidneys and switching on hormone systems.
• Hormones. The renin–angiotensin–aldosterone system squeezes arteries and tells the kidneys to keep salt. In some people it runs too hot. One form, primary aldosteronism, is far more common than doctors used to think: about 6% of people with high blood pressure in primary care, and around 20% of people whose blood pressure won't come down on three medicines. It is very treatable once found, so the new guideline tells doctors to test for it more widely.
• The blood vessels. The lining of healthy arteries releases nitric oxide, which relaxes them. In high blood pressure that lining works less well. And with age, large arteries stiffen: the top number keeps climbing for life, while the bottom number starts falling after about 50 or 60. That is why so many older adults have only the top number high.
• The nervous system. The "fight or flight" system tends to be turned up in people with high blood pressure, tightening arteries and speeding the heart.
• Genes. Somewhere between about 30% and 60% of the differences in blood pressure between people are inherited. But there is no single blood pressure gene. The largest studies have found thousands of genetic variants, each nudging pressure up or down by a tiny amount. Together, the variants found so far explain only around 6–7% of the differences in systolic pressure.
• Life. One major review estimates that excess weight accounts for two-thirds to three-quarters of the risk of primary high blood pressure. Salt raises it, potassium lowers it, heavy drinking raises it, and inactivity raises it. Sleep apnea is found in most people with hard-to-control blood pressure (60–84%), and in one long-running study, people with moderate to severe sleep apnea had almost three times the odds of developing high blood pressure four years later.

About 5–10% of people have a clear, specific cause (secondary hypertension): an adrenal gland making too much aldosterone, narrowed kidney arteries, kidney disease, thyroid problems, or medicines and drugs such as anti-inflammatory painkillers (ibuprofen, naproxen), decongestants, stimulants and some birth control pills.

The point for patients is simple: if the cause is a mosaic, the fix usually is too. That's why the first-line medicines work on different pieces (diuretics on salt and water, ACE inhibitors and ARBs on the hormone system, calcium-channel blockers on the arteries), and why most people with high blood pressure end up needing more than one approach. Needing two medicines isn't a sign anything has failed. It's a sign the disease has more than one cause.

What it does to your body

High blood pressure isn't dangerous because of the number. It's dangerous because of what years of extra force do to the walls of your arteries and the organs they feed.

In a pooled analysis of a million adults, the risk of dying of a stroke or heart attack roughly doubled with every 20 points of usual systolic pressure above 115. There was no safe threshold: risk kept falling all the way down to at least 115/75.

Over time, that force:

• Thickens and weakens the heart (left ventricular hypertrophy), leading to heart failure and irregular rhythms like atrial fibrillation
• Damages the brain, causing strokes, memory problems and dementia
• Scars the kidneys, which then push blood pressure higher still, a vicious circle
• Damages the arteries in the heart, legs and eyes

Some damage, like a thickened heart wall or protein in the urine, starts early and silently. The catastrophic events usually come after years of uncontrolled pressure. That long silent window is exactly where treatment does its work.

"Treat the root cause, not the symptom"

This is the pitch you'll hear from a lot of wellness influencers and "root cause" practitioners: your doctor just covers up the symptom with a pill. We find out why it's happening and fix that. It sounds like better medicine. For blood pressure, it falls apart on every point.

High blood pressure isn't a symptom. A symptom is something you feel. Most people with high blood pressure feel nothing. The pressure is the injury itself: it is the force that thickens the heart, scars the kidneys and bursts the small vessels in the brain. Bringing it down doesn't cover up a warning light. It turns down the force doing the damage, and in trials, lowering it prevents strokes, heart attacks and deaths (more on that below).

For most people, there is no single root cause to find. For 90–95% of people with high blood pressure, the cause is the mosaic: kidneys, hormones, nerves, arteries, genes and life, all at once. Some of those pieces nobody can change. No protocol rewrites the thousands of gene variants you inherited, and no supplement un-stiffens a 70-year-old aorta. Promising one hidden, fixable cause to everyone means promising most people something that isn't there.

When there is a root cause, ordinary medicine is what finds it. The specific causes are real, and the 2025 guideline tells doctors to look for them. It recommends basic blood and urine tests for everyone with high blood pressure, including kidney function, potassium, blood sugar and thyroid. It recommends screening for primary aldosteronism, with a simple blood test of aldosterone and renin, in anyone whose blood pressure won't come down on three medicines, anyone with low potassium, anyone with sleep apnea, and anyone with a stroke before 40 or a family history of early high blood pressure. And when blood pressure won't come down, it tells doctors to review every medicine the patient takes and stop the ones that push pressure up. None of this needs a special program. It needs a primary care doctor, a blood test, a sleep study and an honest look at your medicine cabinet.

When doctors at one clinic searched hard for a cause in 125 people whose blood pressure stayed high on three or more medicines, they found sleep apnea in 64%, primary aldosteronism in 5.6% and narrowed kidney arteries in 2.4%. In 34.4%, they found no specific cause at all, after a thorough search, in exactly the patients most likely to have one.

And the fix for a root cause is often still a pill. The most common hormone cause, primary aldosteronism, is treated either with surgery, when one adrenal gland is responsible, or with a blood pressure medicine that blocks aldosterone. Finding the cause is good medicine. It just doesn't mean you get to skip the medicine.

Blood pressure pills aren't aimed at the symptom. They're aimed at the mechanism. Each first-line class works on a specific piece of the mosaic:

• Thiazide diuretics block a salt transporter in the kidney, so the kidneys let go of the extra salt and water they've been holding.
• ACE inhibitors stop the body making angiotensin II, and ARBs block it from acting. Both turn down the hormone system that squeezes arteries and keeps salt.
• Calcium-channel blockers block calcium channels in the muscle of the artery wall, so the arteries relax.
• Aldosterone blockers (spironolactone, eplerenone) block aldosterone directly, and are the standard add-on when blood pressure won't come down.

That's not masking. That's targeting the cause, one mechanism at a time, which is the only way a disease with many causes can be treated.

The "root cause" camp is right about one thing: lifestyle is a real cause, and for many people the biggest one. Excess weight alone may account for most of the risk. But that's not a secret mainstream medicine is hiding. The guideline puts lifestyle change first, for everyone, and the next section shows exactly what it asks for. The question isn't root cause or pill. It's what to do while the root cause is being worked on, and what to do for the parts of the mosaic that can't be changed.

So here's the test for anyone selling a root-cause fix for blood pressure: which piece of the mosaic does it change, by how many points, and in what trial did it prevent a single stroke?

What the guideline tells doctors to do

The current US guideline, published in 2025 by the American Heart Association, the American College of Cardiology and 11 other organisations, sets out a clear pathway.

1. Measure it properly. A single reading isn't enough to diagnose anything. Seated with your back supported and feet flat, after five minutes of quiet rest, with a cuff that fits a bare arm, no talking, no phone, no coffee or cigarette in the past half hour. The diagnosis should rest on an average of at least two readings on at least two occasions, and be confirmed outside the office with a home monitor or a 24-hour monitor, because some people only run high in a clinic (white-coat hypertension). At home, the guideline suggests two readings a minute apart, morning and evening, for three to seven days. Smartwatches and cuffless devices are not accurate enough yet.

2. Work out your risk. For people with stage 1 high blood pressure, the decision about medication depends on your overall risk. If you already have heart disease or have had a stroke, or you have diabetes or kidney disease, you count as higher risk automatically. Otherwise doctors use the PREVENT calculator, which estimates your chance of a heart attack, stroke or heart failure over 10 years. The line is 7.5%.

3. Lifestyle for everyone, medication by risk.

• Elevated (120–129/under 80): lifestyle changes, recheck in 3–6 months.
• Stage 1, higher risk: lifestyle plus one medicine, recheck in a month.
• Stage 1, lower risk: lifestyle changes for 3 to 6 months. If your blood pressure is still 130/80 or higher after that, the guideline now recommends medication. Lifestyle-only is a trial period, not a permanent plan.
• Stage 2 (140/90 or higher): lifestyle plus two medicines from the start, ideally combined in one pill, recheck in a month.

4. Use the proven medicines. First-line choices are thiazide-type diuretics, long-acting calcium-channel blockers like amlodipine, and ACE inhibitors or ARBs like lisinopril and losartan. Beta-blockers are kept for people with a specific reason to take them, such as some heart conditions.

5. Treat to target, and keep checking. The goal is under 130/80 for nearly all adults, with encouragement to get the top number under 120. Follow-up is monthly until you're there, then every 3 to 6 months. The guideline also now says, for the first time with its strongest recommendation, that keeping the top number under 130 helps prevent memory problems and dementia.

The lifestyle advice in the guideline is specific: lose at least 5% of your body weight if you're carrying extra; eat a DASH-style diet; keep sodium under 2,300 mg a day, ideally under 1,500 mg; eat more potassium (unless you have kidney disease or take drugs that raise potassium); consider a potassium-based salt substitute; aim for 90 to 150 minutes a week of structured exercise; and drink no alcohol, or at most one drink a day for women and two for men. Keep that list in mind. We'll come back to who can actually do it.

What a blood pressure pill does

This is one of the best-studied questions in medicine. A 2016 analysis pooled 123 trials and more than 600,000 people. For every 10 points the top number came down:

• Strokes fell 27%
• Heart failure fell 28%
• Major cardiovascular events fell 20%
• Deaths from any cause fell 13%

A 2021 analysis of the individual records of 344,716 trial participants found the benefit held even in people whose blood pressure wasn't especially high to begin with: roughly 10% fewer major events for every 5 points.

It holds at the oldest ages too. In a trial of people aged 80 and over, treatment cut deaths from any cause by 21% and heart failure by 64%, and the treated group had fewer serious side effects than the group on placebo.

There is one honest exception. For people with mild high blood pressure (140–159 over 90–99) and no heart disease, the evidence is genuinely disputed. A Cochrane review of four trials found no clear drop in deaths or events, and 9% of people stopped treatment because of side effects. A larger analysis found that treatment did reduce deaths and strokes, but most of its data came from people with diabetes. This is exactly the low-risk group that guidelines tell to try lifestyle first.

How many years a pill buys

Percentages are abstract. Years aren't.

• About five years of life. In the long-running Framingham study, people who reached 50 with normal blood pressure lived about 5 years longer than those with high blood pressure, and men lived 7 more years free of heart disease. A study of 1.25 million people in England found that high blood pressure brought cardiovascular disease on five years earlier.
• Nearly three years from tighter control. The SPRINT trial treated adults over 50 at raised heart risk to a top number under 120 instead of under 140. A later analysis projected that the tighter target added 2.9 years of life for someone starting at 50 and 1.1 years at 65. That's a projection from three years of trial data, but it is anchored in a randomised trial.
• A small number of people to treat. In SPRINT, for every 61 people treated to the tighter target for about three years, one heart attack, stroke, heart failure or cardiovascular death was prevented. For every 90, one death from any cause was prevented.
• The benefit outlasts the pills. In an older trial of adults over 60, people given a diuretic for four and a half years, before everyone was offered treatment, still had about 158 more days free of cardiovascular death 22 years later. That's roughly a day for every month of treatment. (The difference in deaths from all causes was smaller and not statistically certain.)

These are different kinds of evidence, and none is perfect. But they point the same way, and none points the other way.

What lifestyle changes do

They work, and some work about as well as a pill. These are the reductions in systolic blood pressure seen in controlled trials of people with high blood pressure:

That's a real result, and it's why every guideline puts lifestyle first. A DASH-style diet (vegetables, fruit, low-fat dairy, whole grains, less red meat and sugar) lowered blood pressure by more than one standard-dose pill. Eating more potassium lowers the top number by about 3.5 points in people with high blood pressure.

But look at how those numbers were produced. In the DASH trial, researchers supplied the food. Exercise trials are often supervised. Most lasted weeks or months. The question that matters to a patient is what happens a year or two later, at home, without the support.

Does it last?

This is where lifestyle-only management usually falls down.

• Weight comes back. In a large US trial, people in the weight-loss group had lost 4.4 kg (about 10 lb) at 6 months, 2.0 kg at 18 months and just 0.2 kg at three years. Across 29 US weight-loss programmes, people kept off about 3 kg after five years, a fifth to a quarter of what they first lost.
• The blood pressure effect fades. In the PREMIER trial, a comprehensive lifestyle programme cut the number of people with high blood pressure sharply at 6 months. By 18 months, the difference in blood pressure compared with simple advice was no longer statistically significant.
• Those who stick with it do very well. In that same weight-loss trial, people who kept off at least 4.5 kg had 65% lower odds of developing high blood pressure. The problem isn't that lifestyle doesn't work. It's that most people can't keep it up.

Only a handful of lifestyle trials have followed people long enough to count heart attacks, strokes and deaths:

• Among US adults with slightly raised blood pressure, cutting salt in two trials led to 25% fewer cardiovascular events over 10 to 15 years. The drop in deaths wasn't statistically clear.
• The strongest result is from a trial of 21,000 people in rural China at high risk of stroke. Swapping ordinary salt for a potassium salt substitute led to 14% fewer strokes and 12% fewer deaths. Notice what that intervention is: a cheap swap that takes no willpower, not a request to overhaul your life.
• An intensive diet-and-exercise programme in people with type 2 diabetes (Look AHEAD) did not reduce heart attacks or strokes, despite weight loss.

Medication isn't easy to keep up either: in one large study, about half of people had stopped their blood pressure medicine within a year. But restarting a pill is easier than rebuilding a diet, and a pill's effect doesn't depend on your week.

Who dies of it first

High blood pressure doesn't fall evenly.

• It comes earlier for Black Americans. In a study that followed young adults from their 20s, three in four Black men and women had developed high blood pressure by 55, against just over half of white men and 40% of white women. Even among people who started with excellent blood pressure, Black participants were about twice as likely to develop it. Today, 46.9% of Black adults have blood pressure of 140/90 or higher, against 29.7% of white adults.
• It kills more Black Americans. Hypertension-related deaths from heart disease and stroke run about 1.8 times higher in Black men than white men, and 1.6 times higher in Black women than white women.

• It is the biggest single reason for the racial gap in early death. A national study of years of potential life lost found that high blood pressure accounted for 15% of the difference between Black and white Americans, more than any other single condition. Those data are from the 1980s and 90s, but blood pressure gaps remain. A 2025 model estimated that closing the gap in average systolic pressure between Black and white adults would prevent roughly 77,000 cardiovascular deaths over 10 years.
• It's getting worse, not better, overall. Hypertension-related cardiovascular deaths rose from 171,259 in 2000 to 270,839 in 2018, with rates climbing again since 2012, including among white men. Between 2007 and 2017, hypertension-related cardiovascular death rates rose 72% in rural America, against 20% in cities, according to an analysis in the Journal of the American College of Cardiology.
• Money is a life expectancy. Across all causes of death, the richest 1% of American men live 14.6 years longer than the poorest 1% (10.1 years for women), measured from age 40. Blood pressure is one of the pathways: people with the least education have about twice the odds of high blood pressure, and the poorest are the least likely to have it under control.

Among people with high blood pressure, 43% of those below the poverty line had it under control, against 55% of those with the highest incomes. Without insurance, only 24% were controlled, against 48% with private insurance. People who hadn't seen a clinician in a year: 8%. And about 1 in 10 adults with high blood pressure skip doses or stretch prescriptions to save money.

What each path costs

The pills are cheap. Most first-line blood pressure medicines are decades-old generics. At Walmart's 2025 prices, hydrochlorothiazide, losartan-hydrochlorothiazide and lisinopril-hydrochlorothiazide cost $4 a month or $10 for three months. Amlodipine, lisinopril and losartan cost $9 a month or $24 for three months. That's roughly $40 to $100 a year paying cash.

Healthy food costs more. In a review of studies from around the world, the healthiest diets cost about $1.50 more per person per day than the least healthy: roughly $550 a year. In the US, people who ate the most DASH-like diet spent about 19% more on food, and the gap was larger for Black Americans.

That flips a common assumption. For many patients, the lifestyle route costs more out of pocket than the pills.

Uncontrolled blood pressure costs the most. People with high blood pressure spend about $1,920 more a year on healthcare than people without it, about $131 billion a year across the US. Strokes alone cost the country about $56 billion a year. Treating high blood pressure to guideline targets is estimated to prevent about 56,000 cardiovascular events and 13,000 deaths a year in the US, and treating people with stage 2 high blood pressure or existing heart disease saves money overall.

“Just change your lifestyle” is a privilege

Picture a mother of four working two jobs.

She isn't rare. 78% of unmarried mothers in the US are in the workforce, and about 1 in 15 Black women, and the same share of divorced, separated or widowed women, hold more than one job. Rotating shift work, common in healthcare, factories and warehouses, is linked to 34% higher odds of high blood pressure. If she's Black, her chance of developing high blood pressure by 55 is about three in four.

Now hand her the guideline's lifestyle list. Ninety to 150 minutes a week of structured exercise, when the average American adult manages about 20 minutes a day of exercise or sport of any kind, and fewer than 1 in 4 do any on a given day. Healthier food that costs, on average, about $550 a year more per person, multiplied by five people, bought from a store that, for about a third of low-income Americans, is more than a mile away. Meals cooked from scratch, when people with the least time to cook are the ones who eat the most fast food. And then keep all of it up for years, because in the trials the benefit faded when people stopped.

For people who can do that, it's brilliant. Many of them will lower their blood pressure, and some will never need a pill. But being able to do it is a privilege: of time, money, a safe place to walk, a kitchen, a schedule that's yours. Lifestyle advice isn't wrong. It just lands very differently on a salaried professional with a gym downstairs than on someone working rotating shifts with a corner store for a grocery.

The evidence doesn't show that doctors mostly give "lifestyle only" advice to wealthier patients. Under the 2017 guideline, the 22% of adults recommended lifestyle alone skewed young, and many weren't in regular care at all: 20% were uninsured and 22% hadn't seen a doctor in a year. The privilege isn't in who gets the advice. It's in who can follow it.

Which is why the louder message online, that blood pressure pills are dangerous and real health comes from lifestyle and natural remedies, isn't just wrong. It's cruel. Telling that mother that the $4 pill is poison, and that the healthy choice is the one she has no time or money to make, is telling her that ten extra years of life are for people who can afford them. She has the same right to those years as anyone else. A pill that costs less than a coffee a month is one of the most equalising tools in medicine. Talking her out of it doesn't make her healthier. It makes her one of the 680,000.

What about side effects?

This is the most common reason people give for wanting to avoid pills, and it's a fair question.

Some drug classes do cause more people to stop than placebo: about two to three times as many stop because of side effects on diuretics, beta-blockers, calcium-channel blockers and ACE inhibitors. ACE inhibitors' dry cough is the classic example. Angiotensin receptor blockers (ARBs, such as losartan) were no different from placebo. There's a small rise in dizziness, fainting, potassium problems and kidney strain, so blood tests and follow-up matter.

But in the large SPRINT trial, people who took about one extra drug to push their blood pressure lower reported no worse quality of life, mood or satisfaction. Lifestyle programmes, for their part, improved some quality-of-life scores, mostly in people who lost weight. Both can be done without feeling worse. And if one medicine doesn't suit you, there are four first-line families to choose from.

The bottom line

High blood pressure is a mosaic: genes, kidneys, hormones, arteries, weight, salt, sleep and stress, usually several at once. It does its damage silently, roughly doubling your risk of dying of a stroke or heart attack with every 20 points. Treating it is one of the best-proven things in all of medicine: fewer strokes, less heart failure, fewer deaths, and years of life.

Lifestyle changes genuinely work, and the guideline recommends them for everyone. But no trial shows that lifestyle alone protects you as well as medication against strokes, heart attacks and early death, the effects usually fade within a year or two, the healthy route often costs more than the pills, and the people with the highest blood pressure are the least likely to have the time, money and neighbourhood to make the changes stick.

The evidence points to both, not either-or. Make the changes you can; even a salt substitute counts. Give it a few months if your doctor says your risk is low. And if your numbers are still high, taking a pill isn't failing at lifestyle. It's the cheapest, best-proven protection medicine has, and you deserve it as much as anyone.

If you have high blood pressure, ask what your 10-year risk is, check your pressure at home, and ask when you'll recheck. And if cost is why you're skipping doses, say so: there's almost always a cheaper option.

Sources

1. Fryar CD, et al. Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United States, August 2021–August 2023. NCHS Data Brief No. 511. 2024.
2. CDC. High blood pressure facts.
3. Oparil S, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014.
4. Guyton AC. Blood pressure control: special role of the kidneys and body fluids. Science. 1991;252:1813–1816.
5. Franklin SS, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation. 1997;96:308–315.
6. Page IH. Pathogenesis of arterial hypertension. JAMA. 1949;140:451–458.
7. Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of hypertension: the mosaic theory and beyond. Circ Res. 2021;128:847–863.
8. Kupper N, et al. Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension. 2005;45:80–85.
9. Evangelou E, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412–1425.
10. Keaton JM, et al. Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nat Genet. 2024;56:778–791.
11. Hall JE, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116:991–1006.
12. Aburto NJ, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378.
13. Carey RM, et al. Resistant hypertension: detection, evaluation, and management. A scientific statement from the American Heart Association. Hypertension. 2018;72:e53–e90.
14. Peppard PE, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378–1384.
15. Monticone S, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–1820.
16. Brown JM, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10–20.
17. Pedrosa RP, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811–817.
18. Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
19. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370:591–603.
20. Jones DW, et al. 2025 AHA/ACC guideline for the prevention, detection, evaluation and management of high blood pressure in adults. J Am Coll Cardiol. 2025;86:1567–1678.
21. Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967.
22. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. Lancet. 2021;397:1625–1636.
23. Diao D, et al. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;CD006742.
24. Sundström J, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162:184–191.
25. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.
26. Vaduganathan M, et al. Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of SPRINT. JAMA Cardiol. 2020;5:576–581.
27. Kostis JB, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011;306:2588–2593.
28. Beckett NS, et al. Treatment of hypertension in patients 80 years of age or older (HYVET). N Engl J Med. 2008;358:1887–1898.
29. Franco OH, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46:280–286.
30. Rapsomaniki E, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899–1911.
31. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.
32. Appel LJ, et al. A clinical trial of the effects of dietary patterns on blood pressure (DASH). N Engl J Med. 1997;336:1117–1124.
33. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure. BMJ. 2013;346:f1325.
34. Neter JE, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–884.
35. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004473.
36. Roerecke M, et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e108–e120.
37. Stevens VJ, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134:1–11.
38. Elmer PJ, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of the PREMIER trial. Ann Intern Med. 2006;144:485–495.
39. Anderson JW, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579–584.
40. Cook NR, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885.
41. Neal B, et al. Effect of salt substitution on cardiovascular events and death (SSaSS). N Engl J Med. 2021;385:1067–1077.
42. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
43. Vrijens B, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–1117.
44. Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002;347:1585–1592.
45. Rethy L, et al. Trends in hypertension-related cardiovascular mortality in the United States, 2000 to 2018. Hypertension. 2020;76:e23–e25.
46. Thomas SJ, et al. Cumulative incidence of hypertension by 55 years of age in Blacks and Whites: the CARDIA Study. J Am Heart Assoc. 2018;7:e007988.
47. Hardy ST, et al. Trends in blood pressure control among US adults with hypertension, 2013–2014 to 2021–2023. Am J Hypertens. 2025;38:120–128.
48. Hardy ST, et al. Prevention of cardiovascular disease events and deaths among Black adults via systolic blood pressure equity. JAMA Netw Open. 2025;8:e2541336.
49. Nambiar L, et al. Decade-long temporal trends in U.S. hypertension-related cardiovascular mortality. J Am Coll Cardiol. 2020;75:2644–2646 (figures as reported in the ACC's press release, 19 March 2020).
50. Chetty R, et al. The association between income and life expectancy in the United States, 2001–2014. JAMA. 2016;315:1750–1766.
51. Million Hearts (US Department of Health and Human Services). Estimated hypertension prevalence, treatment, and control among U.S. adults.
52. Muntner P, et al. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324:1190–1200.
53. Kirkland EB, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003–2014. J Am Heart Assoc. 2018;7:e008731.
54. Moran AE, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015;372:447–455.
55. Walmart. Guide to low-cost prescriptions (effective 24 March 2025).
56. Rao M, et al. Do healthier foods and diet patterns cost more than less healthy options? A systematic review and meta-analysis. BMJ Open. 2013;3:e004277.
57. Monsivais P, Rehm CD, Drewnowski A. The DASH diet and diet costs among ethnic and racial groups in the United States. JAMA Intern Med. 2013;173:1922–1924.
58. CDC. Stroke facts and statistics.
59. Jackson SL, et al. Characteristics of US adults recommended for lifestyle modification only under the 2017 hypertension guideline. Am J Hypertens. 2021;34:348–358.
60. Leng B, et al. Socioeconomic status and hypertension: a meta-analysis. J Hypertens. 2015;33:221–229.
61. Fang J, et al. Cost-related non-adherence to antihypertensive medication among US adults. Am J Hypertens. 2020;33:879–886.
62. US Bureau of Labor Statistics. Current Population Survey, Table 36: Multiple jobholders by selected characteristics (2024 annual averages).
63. US Bureau of Labor Statistics. Employment characteristics of families, 2025.
64. US Bureau of Labor Statistics. American Time Use Survey, 2025 results, Table 1.
65. Seligman HK, Laraia BA, Kushel MB. Food insecurity is associated with chronic disease among low-income NHANES participants. J Nutr. 2010;140:304–310.
66. Rhone A, Williams R, Dicken C. Low-income and low-foodstore-access census tracts, 2015–19. USDA Economic Research Service, EIB-236. 2022.
67. Monsivais P, Aggarwal A, Drewnowski A. Time spent on home food preparation and indicators of healthy eating. Am J Prev Med. 2014;47:796–802.
68. Manohar S, et al. Associations of rotational shift work and night shift status with hypertension: a systematic review and meta-analysis. J Hypertens. 2017;35:1929–1937.
69. Chiu M, et al. Moving to a highly walkable neighborhood and incidence of hypertension: a propensity-score matched cohort study. Environ Health Perspect. 2016;124:754–760.
70. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs. J Hypertens. 2016;34:1921–1932.
71. Berlowitz DR, et al. Effect of intensive blood-pressure treatment on patient-reported outcomes (SPRINT). N Engl J Med. 2017;377:733–744.